44 results on '"Scilipoti, Pietro"'
Search Results
2. Long-term functional outcomes in patients undergoing radical nephrectomy for renal cell carcinoma and tumor thrombus
3. Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical template of lymph node dissection during nephrectomy
4. Challenging cases in high-risk prostate cancer patients treated with Retzius-sparing robot-assisted radical prostatectomy
5. Risk of prostate cancer death in men diagnosed with prostate cancer at cystoprostatectomy. A nationwide population-based study
6. #2071 The metabolic syndrome impact in the onco-nephrological scenario of renal cancer: when comorbidities beat surgery
7. PD41-10 UROLOGICAL FOLLOW-UP OF LYNCH SYNDROME: UTUC INCIDENCE AND MUTATIONAL PATTERNS IN A DEDICATED OUTPATIENT CLINIC
8. MP77-11 NOMOGRAM PREDICTING OPTIMAL CANDIDATES FOR BLADDER-SPARING STRATEGIES AFTER NEOADJUVANT IMMUNOTHERAPY
9. PD45-05 WHEN DOES SYSTEMATIC BIOPSY INFORMATION MATTER THE MOST? IDENTIFYING INDEPENDENT PREDICTORS OF DISEASE DOWNGRADING AT RADICAL PROSTATECTOMY IN HIGH GRADE PROSTATE CANCER BASED ON A LARGE MULTI-INSTITUTIONAL SERIES
10. MP71-15 CANCER CONTROL RATES IN ADEQUATE VERSUS INADEQUATE TREATMENT WITH ADJUVANT IMMUNOTHERAPY INSTILLATIONS WITH BCG
11. PD57-10 AGE-DEPENDENT EFFECT OF EARLY SALVAGE RADIOTHERAPY FOR BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY
12. MP14-11 THE ADDED VALUE OF CONCOMITANT WHOLE-PELVIS SALVAGE RADIATION THERAPY IN OLIGO-RECURRENT PROSTATE CANCER PATIENTS TREATED WITH METASTASIS-DIRECTED THERAPY FOR DISTANT POSITIVE UPTAKES AT PSMA PET
13. MP05-20 WHOLE EXOME SEQUENCING ANALYSIS IN LOW-RISK PROSTATE CANCER PATIENTS WITH KNOWN FAMILY HISTORY. IMPLICATION FOR ACTIVE SURVEILLANCE
14. MP71-07 THE IMPACT OF CENTRALIZED UROPATHOLOGY REVIEW IN THE MANAGEMENT OF BLADDER CANCER PATIENTS AT THE TIME OF TRANSURETHRAL RESECTION OF THE BLADDER
15. MP16-11 LONG-TERM OUTCOMES OF PTA HIGH GRADE INTERMEDIATE AND HIGH RISK BLADDER CANCER PATIENTS
16. MP53-18 IMPACT OF NEOADJUVANT CHEMO-IMMUNOTHERAPY ON INTRA AND POST OPERATIVE OUTCOMES IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY AND PELVIC LYMPH NODE DISSECTION: PROSPECTIVE SURGICAL ASSESSMENT FROM THE NURE-COMBO TRIAL
17. MP53-02 RISK OF NODE METASTASES IN MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMO- OR IMMUNOTHERAPY AND RADICAL CYSTECTOMY WITH BILATERAL PELVIC LYMPH NODE DISSECTION
18. PD38-03 DETECTION OF LYMPH NODE INVOLVEMENT BEFORE RADICAL CYSTECTOMY: DIAGNOSTIC PERFORMANCE OF 18F-FDG PET/CT AND IMPLICATIONS IN THE THERAPEUTIC MANAGEMENT
19. PD30-01 DEFINING INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER: A COMPARATIVE STUDY OF EAU AND IBCG CRITERIA
20. MP37-20 THE EFFECT OF PENILE REHABILITATION AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY ON URINARY CONTINENCE AND ERECTILE FUNCTION RECOVERY. RESULTS FROM a HIGH-VOLUME, SINGLE-SURGEON SERIES
21. PD61-04 LONG-TERM ONCOLOGICAL OUTCOMES OF SURGICALLY MANAGED VERY HIGH-RISK PROSTATE CANCER PATIENTS ACCORDING TO THE STAMPEDE TRIAL DEFINITION: IMPLICATIONS FOR THE SELECTION OF CANDIDATES FOR CLINICAL TRIALS
22. Use of 18F‐fluoro‐2‐deoxy‐d‐glucose (18F‐FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients.
23. Long‐term functional outcomes after robot‐assisted radical cystectomy with intracorporeal ileal orthotopic neobladder
24. PD46-06 UROLOGICAL FOLLOW-UP AND MUTATIONAL PATTERNS IN LYNCH SYNDROME PATIENTS: A SINGLE CENTER EXPERIENCE
25. MP63-19 ADEQUATE VS INADEQUATE BCG INTRAVESICAL THERAPY IN INTERMEDIATE AND HIGH RISK NMIBC: TOTAL NUMBER OF INSTILLATIONS IS WHAT REALLY MATTERS
26. MP11-11 TAILORING THE OPTIMAL USE OF ANDROGEN-DEPRIVATION THERAPY CONCOMITANT TO POST-OPERATIVE RADIOTHERAPY AMONG MEN WITH PN1 PROSTATE CANCER. LONG-TERM RESULTS OF A LARGE, SINGLE INSTITUTION SERIES
27. MP46-08 DIAGNOSTIC PERFORMANCE OF PET-CT COMPARED TO CONVENTIONAL CT FOR LYMPH NODE STAGING IN BLADDER CANCER PATIENTS UNDERGOING RADICAL CYSTECTOMY AND BILATERAL PELVIC LYMPH NODE DISSECTION
28. PD39-10 THE ASSOCIATION BETWEEN PSA DENSITY AND THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER ACROSS ALL PIRADS SCORES IN MEN WITH POSITIVE MPMRI. WHEN PSA DENSITY CAN HELP AVOIDING PROSTATE BIOPSY?
29. MP61-14 PSMA RADIO-GUIDED SURGERY TO DETECT NODAL METASTASES IN PROSTATE CANCER PATIENTS UNDERGOING ROBOT-ASSISTED RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION: UPDATED RESULTS OF PLANNED INTERIM ANALYSES OF A PROSPECTIVE PHASE 2 STUDY
30. MP67-04 VALIDATION OF NOVEL PREOPERATIVE RISK CATEGORIES ON THE PREDICTION OF CLINICAL RECURRENCE IN PATIENTS CANDIDATE FOR RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER. RESULTS OF A LARGE, MULTI-INSTITUTIONAL SERIES
31. MP38-18 INCORPORATING THE PRECISE RECOMMENDATIONS TO EVALUATE PROGRESSION IN MEN ON ACTIVE SURVEILLANCE FOR LOW-GRADE PROSTATE CANCER: WHICH PATIENTS WITH LOW PRECISE SCORE NEED A CONFIRMATORY BIOPSY?
32. MP08-14 LONG TERM OUTCOMES OF REPEATED MITOMYCIN C INSTILLATION IN LOW RISK AND INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
33. MP11-08 EXPLORING THE EFFECT OF METASTASIS DIRECTED THERAPY ON PROGRESSION PATTERNS OF PATIENTS WITH POSITIVE 68Ga-PSMA PET/CT AND BIOCHEMICAL RECURRENCE FROM PROSTATE CANCER
34. MP67-07 CAN WE PREDICT THE SITE OF POSITIVE SURGICAL MARGINS (PSM) BASED ON THE SITE OF THE INDEX LESION AT MULTIPARAMETRIC MRI? A TOPOGRAPHIC SINGLE CENTER STUDY
35. PD39-09 IMPACT OF PROSTATE IMAGING QUALITY (PI-QUAL) SCORE ON THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN UNDERGOING MRI-TARGETED BIOPSY
36. V07-06 RETZIUS-SPARING ROBOT-ASSISTED RADICAL PROSTATECTOMY IN HIGH-RISK PROSTATE CANCER PATIENTS
37. Retzius-sparing Robot-assisted Radical Prostatectomy in High-risk Prostate Cancer Patients: Results from a Large Single-institution Series
38. MP71-14 LONG TERM OUTCOMES OF LOW AND INTERMEDIATE RISK BLADDER CANCER PATIENTS TREATED WITH TRANSURETHRAL RESECTION ELIGIBLE FOR ACTIVE SURVEILLANCE.
39. MP71-10 HEAD-TO-HEAD ONCOLOGICAL OUTCOMES COMPARISON OF MITOMYCIN C VS BACILLUS CALMETTE-GUERIN TREATMENT IN INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS.
40. The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis
41. The Detrimental Effect of Metabolic Syndrome on Long-term Renal Function in Patients Undergoing Elective Partial Nephrectomy for Small Renal Masses.
42. Re: Jeremy Yuen-Chun Teoh, Cheung-Hing Cheng, Chiu-Fung Tsang, et al. Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.04.015.
43. Mitomycin C vs. Bacillus Calmette-Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients-A comparative analysis from a single center.
44. The Impact of Second Opinion Expert Pathology Review in Patient Management at the Time of Transurethral Resection of the Bladder.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.